CD36: The Bridge between Lipids and Tumors

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

It has been found that the development of some cancers can be attributed to obesity, which is associated with the excessive intake of lipids. Cancer cells undergo metabolic reprogramming, shifting from utilizing glucose to fatty acids (FAs) for energy. CD36, a lipid transporter, is highly expressed in certain kinds of cancer cells. High expressions of CD36 in tumor cells triggers FA uptake and lipid accumulation, promoting rapid tumor growth and initiating metastasis. Meanwhile, immune cells in the tumor microenvironment overexpress CD36 and undergo metabolic reprogramming. CD36-mediated FA uptake leads to lipid accumulation and has immunosuppressive effects. This paper reviews the types of FAs associated with cancer, high expressions of CD36 that promote cancer development and progression, effects of CD36 on different immune cells in the tumor microenvironment, and the current status of CD36 as a therapeutic target for the treatment of tumors with high CD36 expression.

Cite

CITATION STYLE

APA

Zhou, X., Su, M., Lu, J., Li, D., Niu, X., & Wang, Y. (2024, January 1). CD36: The Bridge between Lipids and Tumors. Molecules. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/molecules29020531

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free